Literature DB >> 3113156

Coagulation changes in sickle cell disease in early childhood.

M A Babiker, E F Ashong, H Bahakim, A M Gader.   

Abstract

Measurements of the coagulation system were carried out in children with sickle cell disease (SCD) in both steady state and on the 1st day of painful crisis and were compared to age- and sex-matched healthy controls. No significant differences were found in prothrombin time, partial thromboplastin time, thrombin time, reptilase time, plasma fibrinogen, antithrombin III, factor VIII:C, ristocetin-cofactor (Ri-Cof) and platelet aggregation responses to ADP, collagen and adrenaline. Abnormal aggregation responses to ristocetin were noted in all patients with SCD when compared to controls. Daily measurements during the first 4 days of painful crisis showed significant elevation of fibrinogen and Ri-Cof and enhancement of aggregation to ADP and adrenaline by the 3rd day of crisis. It was concluded that the changes noted, rather than being primarily responsible for the onset of crisis, can only be secondary changes arising from the aetiological factors of crisis, i.e. stasis and acute-phase proteins.

Entities:  

Mesh:

Year:  1987        PMID: 3113156     DOI: 10.1159/000205981

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

Review 1.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

Authors:  Marilyn J Telen
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

3.  Haemostatic measurements in childhood nephrotic syndrome.

Authors:  A T Elidrissy; M B Abdurrahman; H M Bahakim; M D Jones; A M Gader
Journal:  Eur J Pediatr       Date:  1991-03       Impact factor: 3.183

Review 4.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.